WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 41

Legislative bill overview

SB 41 is a Kentucky bill relating to sickle cell disease that was introduced in the state Senate on January 7, 2025. The bill is currently in early committee review stages, having been referred to the Health Services Committee. Specific provisions have not yet been publicly detailed, as the bill is still in its introductory phase.

Why is this important

Sickle cell disease disproportionately affects African American populations and causes significant health complications including pain, organ damage, and reduced life expectancy. Legislation addressing sickle cell disease could impact healthcare access, screening programs, research funding, or treatment options for affected Kentuckians.

Potential points of contention

  • Funding mechanisms – Whether new programs would require tax increases, budget reallocation, or rely on federal funding
  • Scope of coverage – Disagreement over whether measures should focus on screening, treatment access, research, or patient support services
  • Implementation costs – Debate over the financial burden on the state healthcare system and taxpayers versus public health benefits

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.